Abingworth
Londonabingworth.com
Overview
Abingworth is a transatlantic life sciences investment firm that helps transform cutting-edge science into novel medicines by providing capital and expertise to management teams building world-class companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| AdvanCell | Jul 2026 | Series D | Co-investor |
| cAMPfield Therapeutics | Jun 2026 | Series A | Co-investor |
| cAMPfield Therapeutics | May 2026 | Series A | Co-investor |
| Cytospire Therapeutics | May 2026 | Series A | Co-investor |
| R1 Therapeutics | Mar 2026 | Series A | Lead |
Key People
Kurt von Emster
Managing Partner, Head Of Life Sciences
Tim Haines
Managing Director And Executive Partner
Ibraheem Mahmood
Operating Partner
Carlos Paya
Venture Partner
Natalie Mount
Venture Partner
Andrew Sinclair
Partner, Portfolio Manager
GLH Lloyd-Harris
Partner
Bali Muralidhar
Managing Partner, Chief Investment Officer, Managing Partner
Diya Malhotra
Principal
Graham Mills
Principal
Jay Cui
Principal
Lucille Conroy
Principal
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
